The purpose of this study is to investigate the effects of green tea extract (GTE) on fat oxidation, body composition and exercise performance in overweight individuals. The study will be conducted under laboratory conditions following an 8 week supplemental period. Participants will be required to attend the laboratory for a pre-screening/familiarisation trial followed by assessments at week 0 (baseline), week 2, 4 and 8. Across the intervention, participants will maintain habitual dietary intake and follow a prescribed exercise programme. Additionally participants will be randomised to either a placebo, green tea extract or GTE with antioxidant supplementation. It is hypothesised that the addition of antioxidants with GTE will enhance fat oxidation in overweight individuals more than GTE or placebo. It is further hypothesised that such improvements in fat oxidation due to GTE will lead to improvements in both body composition variables and submaximal exercise performance (metabolic efficiency) in overweight, but otherwise healthy persons.
The health benefits of polyphenols found in green tea (GT), the unfermented leaves of the tea plant, Camellia sinensis, are of current scientific interest. These health benefits, in part, relate to the bioactive catechin polyphenol content of GT, of which (-)-epigallocatechin-3-gallate (EGCG) can account for between 50-80% of the total catechin content. GT catechins have been proposed to influence metabolic and thermogenic activities in the short term, leading to enhanced fat oxidation capacity, although this has been disputed. Research investigating GT extracts (GTE) and exercise have produced conflicting results. Modest EGCG dosage in the short term (270 mg·d-1 EGCG for 6 days, and 68 mg·d-1 EGCG for 3 weeks) did not alter metabolic or performance variables in healthy or endurance trained volunteers. However, the inclusion of 100.5 mg·d-1 EGCG over a 10 week training period enhanced whole-body metabolic efficiency elsewhere. One confounding factor though is the use of caffeinated GTE in these studies. When decaffeinated GTE (dGTE) has been employed, 366 mg EGCG was found to acutely increase fat oxidation by 17%. Indeed a recent publication from our research group investigating the short term use of dGTE demonstrated positive changes in fat oxidation in healthy volunteers. However, less is known as to whether dGTE (or indeed combinations of dGTE with antioxidant nutrients which may improve GTE bioavailability) could provide similar results in overweight or sedentary individuals embarking on an exercise programme. The aim of this research proposal is therefore to assess the impact of two GTE strategies on fat oxidation, cardiometabolic health, visceral fat reduction, and exercise performance in a healthy, but overweight cohort undertaking a standardised exercise training programme. Research Questions: Q1: Does regular consumption of dGTE favourably enhance fat oxidation and/or improve variables associated with cardiometabolic health and body composition in comparison to a placebo supplement in healthy, but overweight individuals? Q2: Does a dGTE complex (including key antioxidant nutrients) enhance fat oxidation and/or improve variables associated with cardiometabolic health and body composition more so than dGTE or placebo supplementation in healthy, but overweight individuals? This study will involve participants attending sessions at Compass House, ARU, undertaking the following: * Baseline trial: all participants will attend a subject briefing, provide written, informed consent prior to participation. Following this, all participants will undertake a baseline test for maximal fat oxidation rates (FATmax) and oxygen uptake using a standardised incremental cycling exercise protocol and expired air analysis * Intervention period: participants will be randomly assigned to either dGTE (400mg EGCG daily), dGTE with antioxidants (150mg quercetin, 150mg alpha-lipoic acid) or placebo for 8 weeks. During this period, participants will undertake regular aerobic exercise (3x/ week; 45mins; at \~ FATmax intensity) * Experimental evaluation of progress will be assessed at weeks 0,2,4, and 8. During laboratory visits, participants will be required to have a single venepuncture blood sample, assessment of blood pressure/ body composition (skinfold, bioelectrical impedance, waist circumference), assessment of FATmax, and assessment of fat oxidation during steady state exercise at FATmax.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
30
8 week supplementation period, with participants consuming 2 capsules per day containing potato starch
8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)
8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
Anglia Ruskin University
Cambridge, United Kingdom
Fat oxidation (max)
Assessment of maximal fat oxidation rate (via expired air) during incremental exercise
Time frame: Change from Baseline maximal fat oxidation at 1 month
Fat oxidation (max)
Assessment of maximal fat oxidation rate (via expired air) during incremental exercise
Time frame: Change from Baseline maximal fat oxidation at 2 months
Fat oxidation (min)
Assessment of exercise intensity at which point fat oxidation is negligable
Time frame: Change from Baseline minimum fat oxidation at 1 month
Fat oxidation (min)
Assessment of exercise intensity at which point fat oxidation is negligable
Time frame: Change from Baseline minimum fat oxidation at 2 months
Height
Assessment of height (in metres)
Time frame: Change from baseline height at 1 month
Height
Assessment of height (in metres)
Time frame: Change from baseline height at 2 months
Weight
Assessment of weight (in kilograms)
Time frame: Change from baseline weight at 1 month
Weight
Assessment of weight (in kilograms)
Time frame: Change from baseline weight at 2 months
Bodyfat percentage
Assessment of bodyfat (%)
Time frame: Change from baseline bodyfat percentage at 1 month
Bodyfat percentage
Assessment of bodyfat (%)
Time frame: Change from baseline bodyfat percentage at 2 months
Waist to hip ratio
Assessment of waist to hip ratio (cm)
Time frame: Change from baseline waist to hip ratio at 1 month
Waist to hip ratio
Assessment of waist to hip ratio (cm)
Time frame: Change from baseline waist to hip ratio at 2 months
Body mass index
Assessment of body mass index or BMI (measured in kilograms per metre squared)
Time frame: Change from baseline BMI at 1 month
Body mass index
Assessment of body mass index or BMI (measured in kilograms per metre squared)
Time frame: Change from baseline BMI at 2 months
Central abdomen depth
Assessment of central abdomen depth (in cm)
Time frame: Change from baseline central abdominal depth at 1 month
Central abdomen depth
Assessment of central abdomen depth (in cm)
Time frame: Change from baseline central abdominal depth at 2 months
Blood cholesterol
Assessment of total cholesterol, triglycerides, HDL-c and LDL-c (all in mmol/L)
Time frame: Change from Baseline at 1 month
Blood cholesterol
Assessment of total cholesterol, triglycerides, HDL-c and LDL-c (all in mmol/L)
Time frame: Change from Baseline at 2 months
Blood glucose
Assessment of blood glucose (in mmol/L)
Time frame: Change from Baseline blood glucose at 1 month
Blood glucose
Assessment of blood glucose (in mmol/L)
Time frame: Change from Baseline blood glucose at 2 months
Blood insulin
Assessment of blood glucose (in pmol/L)
Time frame: Change from Baseline blood insulin at 1 month
Blood insulin
Assessment of blood glucose (in pmol/L)
Time frame: Change from Baseline blood insulin at 2 months
Blood leptin
Assessment of blood leptin (in ng/ml)
Time frame: Change from Baseline blood leptin at 1 month
Blood leptin
Assessment of blood leptin (in ng/ml)
Time frame: Change from Baseline blood leptin at 2 months
Blood adiponectin
Assessment of blood adiponectin (in ug/ml)
Time frame: Change from Baseline blood adiponectin at 1 month
Blood adiponectin
Assessment of blood adiponectin (in ug/ml)
Time frame: Change from Baseline blood adiponectin at 2 months
Blood fatty acids and glycerol
Assessment of blood free fatty acids and glycerol (both in umol/L)
Time frame: Change from Baseline at 1 month
Blood fatty acids and glycerol
Assessment of blood free fatty acids and glycerol (both in umol/L)
Time frame: Change from Baseline at 2 months
Blood liver enzymes
Assessment of blood liver enzymes including alanine aminotransferase(ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) (all measured in U/L)
Time frame: Change from baseline at 1 month
Blood liver enzymes
Assessment of blood liver enzymes including alanine aminotransferase(ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) (all measured in U/L)
Time frame: Change from baseline at 2 months
Blood bilirubin
Assessment of blood concentration of bilirubin (in umol/L)
Time frame: Change from baseline bilirubin at 1 month
Blood bilirubin
Assessment of blood concentration of bilirubin (in umol/L)
Time frame: Change from baseline bilirubin at 2 months
Respiratory measures (oxygen, carbon dioxide) during steady state exercise
Assessment of expired oxygen and carbon dioxide (in litres per minute)
Time frame: Change from baseline at 1 month
Respiratory measures (oxygen, carbon dioxide) during steady state exercise
Assessment of mean expired oxygen and carbon dioxide (in litres per minute)
Time frame: Change from baseline at 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.